Pharmacogenomic test costsaving in depression and anxiety

Pharmacogenomic test costsaving in depression and anxiety PharmacoEconomics & Outcomes News 792, p24 - 2 Dec 2017 Pharmacogenomic test cost saving in depression and anxiety The use of a pharmacogenomic test (IDgenetix) to guide treatment appears to be cost effective in patients with major depressive disorder with or without anxiety, according to findings of an AltheaDx-affiliated study published in PharmacoEconomics. A discrete-event simulation model populated with clinical trial data was used to evaluate the cost effectiveness of IDgenetix-guided treatment compared with treatment as usual in patients with moderate or severe major depressive disorder and/or anxiety, from a US societal perspective over a three-year time horizon. The assumed cost of the IDgenetix test was $2000. The predicted cumulative remission rate was 78% with the IDgenetix strategy versus 66% with usual care, and the estimated QALY gain was 2.09 and 1.94 per patient, respectively. Estimated total costs were $14 124 and $14 659, respectively, resulting in cost savings of $535 per patient in the IDgenetix group. Use of the IDgenetix test was therefore dominant (more effective and less costly) compared with usual care. QALY gains and cost savings were greater in patients with depression with or without comorbid anxiety than in those with anxiety only. Moreover the incremental QALY gain with IDgenetix was higher in patients with severe depression (+0.49) and cost savings were greater ( $6871 per patient). Sensitivity analysis showed that estimated cost savings with the IDgenetix strategy were $6000 over a 10-year time horizon and more than $10 000 over a lifetime time horizon. test on treatment "The impact of the IDgenetix efficacy is larger or, at minimum, comparable to what one might expect from a novel and effective therapeutic option," said the authors. "Overall, several features of the IDgenetix test, such as the efficacy of a guided treatment strategy, one-time test cost, and the prospect of using test results for guiding future episodes of depression or anxiety, make it a potentially dominant strategy compared with usual care," they added. * 2017 US dollars Najafzadeh M, et al. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(R)) to Guide Treatment of Patients with Depression and/or Anxiety. PharmacoEconomics : 6 Nov 2017. Available from: URL: http://doi.org/10.1007/s40273-017-0587-0 803283872 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Pharmacogenomic test costsaving in depression and anxiety

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/pharmacogenomic-test-costsaving-in-depression-and-anxiety-9mIxpgP6TM
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4547-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p24 - 2 Dec 2017 Pharmacogenomic test cost saving in depression and anxiety The use of a pharmacogenomic test (IDgenetix) to guide treatment appears to be cost effective in patients with major depressive disorder with or without anxiety, according to findings of an AltheaDx-affiliated study published in PharmacoEconomics. A discrete-event simulation model populated with clinical trial data was used to evaluate the cost effectiveness of IDgenetix-guided treatment compared with treatment as usual in patients with moderate or severe major depressive disorder and/or anxiety, from a US societal perspective over a three-year time horizon. The assumed cost of the IDgenetix test was $2000. The predicted cumulative remission rate was 78% with the IDgenetix strategy versus 66% with usual care, and the estimated QALY gain was 2.09 and 1.94 per patient, respectively. Estimated total costs were $14 124 and $14 659, respectively, resulting in cost savings of $535 per patient in the IDgenetix group. Use of the IDgenetix test was therefore dominant (more effective and less costly) compared with usual care. QALY gains and cost savings were greater in patients with depression with or without comorbid anxiety than in those with anxiety only. Moreover the incremental QALY gain with IDgenetix was higher in patients with severe depression (+0.49) and cost savings were greater ( $6871 per patient). Sensitivity analysis showed that estimated cost savings with the IDgenetix strategy were $6000 over a 10-year time horizon and more than $10 000 over a lifetime time horizon. test on treatment "The impact of the IDgenetix efficacy is larger or, at minimum, comparable to what one might expect from a novel and effective therapeutic option," said the authors. "Overall, several features of the IDgenetix test, such as the efficacy of a guided treatment strategy, one-time test cost, and the prospect of using test results for guiding future episodes of depression or anxiety, make it a potentially dominant strategy compared with usual care," they added. * 2017 US dollars Najafzadeh M, et al. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(R)) to Guide Treatment of Patients with Depression and/or Anxiety. PharmacoEconomics : 6 Nov 2017. Available from: URL: http://doi.org/10.1007/s40273-017-0587-0 803283872 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Access to DeepDyve database
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off